Topics on this week's Pod include:
-Lurbinectedin in SCLC
-Nivolumab is esophageal cancer
-Pembrolizumab for TMB-high cancers
-Gemtuzumab ozogamicin for pediatric AML
-Venetoclax + HMA for adult (unfit) AML
-Gardasil for prevention of SCCHN
-Perhaps the biggest non-oncopharm news of the year?
